rucaparib may improve pfs in patients with ovarian cancer
Published 4 years ago • 124 plays • Length 1:21Download video MP4
Download video MP3
Similar videos
-
0:43
efficacy of niraparib on pfs in patients with recurrent ovarian cancer
-
1:41
the clinical activity of rucaparib in patients with ovarian cancer
-
2:07
rucaparib in platinum-sensitive ovarian cancer
-
1:27
parp inhibition improves outcomes in patients with brca-mutated ovarian cancer
-
5:11
defining rucaparib’s value in recurrent ovarian cancer
-
4:25
rucaparib: clinical activity in relapsed ovarian cancer
-
3:29
rucaparib boosts pfs in brca-mutated recurrent ovarian cancer
-
2:15
toxicities associated with rucaparib for the treatment of ovarian cancer
-
1:36
dr. coleman discusses the toxicities associated with rucaparib in patients with ovarian cancer
-
3:06
rucaparib maintenance therapy for high-risk ovarian cancer
-
3:15
patients with ovarian cancer likely to respond to rucaparib using tumor genetic analysis
-
3:04
phase ii results for niraparib in heavily pretreated patients with ovarian cancer
-
5:15
fda d.i.s.c.o.: rucaparib in ovarian cancer
-
2:58
rucaparib for relapsed ovarian cancer: safety profile
-
3:11
rucaparib in recurrent ovarian cancer: ariel3 trial
-
1:05
dr. dowdy on bevacizumab and improvement of pfs in ovarian cancer
-
0:58
dr. wright on pfs as an endpoint in ovarian cancer trials
-
5:18
rucaparib for ovarian cancer
-
2:26
dr. mirza discusses niraparib dose modifications for ovarian cancer patients with low body weight